U.S. Physical Therapy, Inc.
NYSE:USPHMedical - Care Facilities
+$0.12 today
- Market cap
- $1.42B
- Beta
- 1.16
- P/E (TTM)
- 810.7
- EPS (TTM)
- $0.08
- Dividend yield
- 2.89%
Volume 0.33M
Average 0.20M
USPH Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
U.S. Physical Therapy, Inc.NYSE: USPH
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $5.37M (cash outflow) rose 108.3% year over year, ahead of the +69.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 36.9% from the prior quarter. Over 3 fiscal years it compounded at +19.5% a year.
Context
- Capital expenditures amounted to 1.8% of revenue in FY2025, up 0.4 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +108.3% holds above the trailing-twelve-month pace of +69.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (14.07M) USD
- Year-over-year change
- -53.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.07M) | -53.2% |
| FY2024 | 2024-12-31 | (9.19M) | +1.2% |
| FY2023 | 2023-12-31 | (9.29M) | -12.7% |
| FY2022 | 2022-12-31 | (8.25M) | -0.6% |
| FY2021 | 2021-12-31 | (8.2M) | — |
Capital Expenditures vs competitors
How USPH compares with its peers on the latest reported figures
- USPH's LTM Mar 2026 capital expenditures of $16.87M is the 8th largest of the 11 companies compared; the peer median is $26.1M.
- Its year-over-year change of +69.9% is the 2nd highest of 11, against a peer median of +3.0%.
- Capital expenditures amounts to 2.3% of revenue for USPH, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $408.02M | +30.0% | -0.8% | 14.3% | |
| LTM Mar 2026 | $229.23M | +3.3% | — | 4.2% | |
| LTM Mar 2026 | $38.69M | -31.1% | -60.0% | 4.9% | |
| LTM Aug 2026 | $35.5M | -60.6% | -7.9% | 4.0% | |
| LTM Jan 2026 | $33.27M | +68.5% | — | 39.7% | |
| LTM Mar 2026 | $18.92M | +27.6% | -3.1% | 1.4% | |
| LTM Mar 2026 | $18.77M | +113.1% | +15.8% | 1.8% | |
| LTM Mar 2026 | $16.87M | +69.9% | +19.5% | 2.3% | |
| LTM Mar 2026 | $11.04M | +2.8% | -23.9% | 0.3% | |
| LTM Mar 2026 | $5.47M | -6.9% | +3.7% | 0.3% | |
| LTM Mar 2026 | $2K | -98.4% | -79.8% | — | |
| Peer median (excluding USPH) | $26.1M | +3.0% | -5.5% | 4.0% | |
Competitors are the stored peer set for USPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 57.92M | 43.41M | 37.22M | 45.6M | 58.01M |
| Depreciation & Amortization | 11.59M | 14.74M | 15.7M | 18.68M | 22.39M |
| Deferred Income Tax | 5.69M | 4.31M | 4.49M | 5.37M | 11.41M |
| Stock-Based Compensation | 7.87M | 7.26M | 7.24M | 7.82M | 8.27M |
| Change in Working Capital | (11.78M) | (21.43M) | (4.93M) | (12.4M) | (27.19M) |
| Accounts Receivables | (10.96M) | (10.28M) | (6M) | (11.89M) | (9.06M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | (7.76M) | 15K | 0 | (7.8M) |
| Other Working Capital | (824K) | (3.4M) | 1.06M | (510K) | (10.33M) |
| Other Non-Cash Items | 5.12M | 10.24M | 22.27M | 9.88M | 2.18M |
| Operating Cash Flow | 76.41M | 58.54M | 81.98M | 74.94M | 75.06M |
| Capital Expenditures | (8.2M) | (8.25M) | (9.29M) | (9.19M) | (14.07M) |
| Acquisitions (Net) | (116.09M) | (74.28M) | (36.87M) | (142.04M) | (24.95M) |
| Purchases of Investments | 0 | (373K) | 0 | 0 | 0 |
| Sales of Investments | 0 | 373K | 0 | 0 | 0 |
| Other Investing Activities | 152K | 1.26M | 1.15M | 1.77M | 2.31M |
| Investing Cash Flow | (124.14M) | (81.27M) | (45.02M) | (149.45M) | (36.71M) |
| Debt Repayment | 93.1M | 64.2M | (39.15M) | 4.3M | 8.06M |
| Common Stock Issued | 0 | 0 | 163.65M | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (5.57M) |
| Dividends Paid | (18.77M) | (21.32M) | (24.13M) | (26.54M) | (27.36M) |
| Other Financing Activities | (30.96M) | (17.12M) | (16.1M) | (14.71M) | (19.27M) |
| Financing Cash Flow | 43.38M | 25.76M | 84.27M | (36.95M) | (44.14M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.35M) | 3.03M | 121.23M | (111.46M) | (5.79M) |
| Free Cash Flow | 68.21M | 50.29M | 72.68M | 65.75M | 60.99M |
U.S. Physical Therapy, Inc.
NYSE:USPH
Intrinsic Alpha fair value
Locked
Current Price
$95.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.